Association of proton pump inhibitors with risk of dementia: A pharmacoepidemiological claims data analysis

JAMA Neurology

Volumn 73, Issue 4, 2016, Pages 410-416

  Gomm, Willy ^a   Von Holt, Klaus ^a   Thomé, Friederike ^a   Broich, Karl ^b   Maier, Wolfgang ^a,c   Fink, Anne ^a,d   Doblhammer, Gabriele ^a,e,f   Haenisch, Britta ^a  

^a GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^b FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d Rostock Center for the Study of Demographic Change   (Germany)

^e MAX PLANCK INSTITUTE FOR DEMOGRAPHIC RESEARCH   (Germany)

^f UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; RABEPRAZOLE; PROTON PUMP INHIBITOR;

AGE DISTRIBUTION; AGED; ARTICLE; COMORBIDITY; DEMENTIA; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOEPIDEMIOLOGY; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; SEX RATIO; VERY ELDERLY; CHEMICALLY INDUCED; COHORT ANALYSIS; INSURANCE; PROCEDURES; PROSPECTIVE STUDY; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

AGED; AGED, 80 AND OVER; COHORT STUDIES; DEMENTIA; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; MALE; PHARMACOEPIDEMIOLOGY; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; RISK FACTORS;

EID: 84963820918     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2015.4791     Document Type: Article

References (33)

1. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108(3):308-328.
2. Londong W, Barth H, Dammann HG, et al. Dose-related healing of duodenal ulcer with the proton pump inhibitor lansoprazole. Aliment Pharmacol Ther. 1991;5(3):245-254.
3. Hollingworth S, Duncan EL, Martin JH. Marked increase in proton pump inhibitors use in Australia. Pharmacoepidemiol Drug Saf. 2010;19(10):1019-1024.
4. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008;336(7634):2-3.
5. Cai S, García Rodríguez LA, Massó-González EL, Hernández-Díaz S. Uncomplicated peptic ulcer in the UK: trends from 1997 to 2005. Aliment Pharmacol Ther. 2009;30(10):1039-1048.
6. Mazer-Amirshahi M, Mullins PM, Van Den Anker J, Meltzer A, Pines JM. Rising rates of proton pump inhibitor prescribing in US emergency departments. Am J Emerg Med. 2014;32(6):618-622.
7. Schwabe U, Paffrath D, eds. Arzneiverordnungs-Report 2014: Aktuelle Daten, Kosten, Trends und Kommentare. Berlin, Germany: Springer; 2014.
8. Pasina L, Nobili A, Tettamanti M, et al; REPOSI Investigators. Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly. Eur J Intern Med. 2011;22(2):205-210.
9. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. Am J Manag Care. 2010;16(9):e228-e234.
10. Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013;310(22):2435-2442.
11. Vogiatzoglou A, Smith AD, Nurk E, et al. Cognitive function in an elderly population: interaction between vitamin B12 status, depression, and apolipoprotein E ϵ4: the Hordaland Homocysteine Study. Psychosom Med. 2013;75(1):20-29.
12. Badiola N, Alcalde V, Pujol A, et al. The proton-pump inhibitor lansoprazole enhances amyloid beta production. PLoS One. 2013;8(3):e58837.
13. Majumdar A, Cruz D, Asamoah N, et al. Activation of microglia acidifies lysosomes and leads to degradation of Alzheimer amyloid fibrils. Mol Biol Cell. 2007;18(4):1490-1496.
14. Pillay CS, Elliott E, Dennison C. Endolysosomal proteolysis and its regulation. Biochem J. 2002;363(pt 3):417-429.
15. Mattsson JP, Väänänen K, Wallmark B, Lorentzon P. Omeprazole and bafilomycin, two proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H+-translocating ATPases. Biochim Biophys Acta. 1991;1065(2):261-268.
16. Fallahzadeh MK, Borhani Haghighi A, Namazi MR. Proton pump inhibitors: predisposers to Alzheimer disease? J Clin Pharm Ther. 2010;35(2):125-126.
17. Haenisch B, Von Holt K, Wiese B, et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci. 2015;265(5):419-428.
18. Jessen F, Kaduszkiewicz H, Daerr M, et al. Anticholinergic drug use and risk for dementia: target for dementia prevention. Eur Arch Psychiatry Clin Neurosci. 2010;260(suppl 2):S111-S115.
19. Chew ML, Mulsant BH, Pollock BG, et al. Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc. 2008;56(7):1333-1341.
20. Ziegler U, Doblhammer G. Prevalence and incidence of dementia in Germany-a study based on data from the public sick funds in 2002 [in German]. Gesundheitswesen. 2009;71(5):281-290.
21. Ferri CP, Prince M, Brayne C, et al; Alzheimer's Disease International. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366(9503):2112-2117.
22. Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol. 2011;7(3):137-152.
23. Wimo A, Jönsson L, Bond J, Prince M, Winblad B; Alzheimer Disease International. The worldwide economic impact of dementia 2010. Alzheimers Dement. 2013;9(1):1-11.
24. Wu YT, Fratiglioni L, Matthews FE, et al. Dementia in western Europe: epidemiological evidence and implications for policy making. Lancet Neurol. 2016;15(1):116-124.
25. Cheng FC, Ho YF, Hung LC, Chen CF, Tsai TH. Determination and pharmacokinetic profile of omeprazole in rat blood, brain and bile by microdialysis and high-performance liquid chromatography. J Chromatogr A. 2002;949(1-2):35-42.
26. Rojo LE, Alzate-Morales J, Saavedra IN, Davies P, Maccioni RB. Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease. J Alzheimers Dis. 2010;19(2):573-589.
27. Querfurth HW, La Ferla FM. Alzheimer's disease. N Engl J Med. 2010;362(4):329-344.
28. O'Leary F, Allman-Farinelli M, Samman S. Vitamin B12 status, cognitive decline and dementia: a systematic review of prospective cohort studies. Br J Nutr. 2012;108(11):1948-1961.
29. Reynolds E. Vitamin B12, folic acid, and the nervous system. Lancet Neurol. 2006;5(11):949-960.
30. Rouch L, Cestac P, Hanon O, et al. Antihypertensive drugs, prevention of cognitive decline and dementia: a systematic review of observational studies, randomized controlled trials and meta-analyses, with discussion of potential mechanisms. CNS Drugs. 2015;29(2):113-130.
31. Doblhammer G, Fink A, Fritze T. Short-term trends in dementia prevalence in Germany between the years 2007 and 2009. Alzheimers Dement. 2015;11(3):291-299.
32. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69(24):2197-2204.
33. Heneka MT, Fink A, Doblhammer G. Effect of pioglitazone medication on the incidence of dementia. Ann Neurol. 2015;78(2):284-294.